/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The BioHub - by Avetix
  2. Episode 245 - Michael Fenn CBO Bexorg
Episode 245 - Michael Fenn CBO Bexorg

Episode 245 - Michael Fenn CBO Bexorg

The BioHub - by Avetix · Oct 14, 2026

Bexorg CBO Michael Fenn discusses bridging the CNS translation gap via whole human brain pharmacology models and precision neurology.

Investors Treat Standalone Biotech Platforms as Cost Centers Without Direct Drug Asset Value

Investors readily calculate risk-adjusted net present value for individual therapeutic assets, whereas platforms are difficult to model financially. Unless a platform directly enhances probability of success, reduces development timelines, or cuts costs for clinical-stage drugs, venture investors often discount it merely as overhead expense.

Episode 245 - Michael Fenn CBO Bexorg thumbnail

Episode 245 - Michael Fenn CBO Bexorg

The BioHub - by Avetix·a month ago

Translating Precision Oncology Biomarkers to Neurology Helps Mitigate Preclinical Translation Risks

Historically, neuroscience has suffered high clinical failure rates due to heterogeneous patient groups, complex pathologies, and subjective, squishy endpoints. Adopting oncology's playbook of validating objective biomarkers and stratifying patient sub-populations before clinical entry allows drug developers to de-risk trials and verify target engagement early.

Episode 245 - Michael Fenn CBO Bexorg thumbnail

Episode 245 - Michael Fenn CBO Bexorg

The BioHub - by Avetix·a month ago

Repeatable Platform-Asset Fit Proves Biotech Technology Value Rather Than One-Off Discoveries

A platform company must prove it can repeatedly produce unique assets with differentiated efficacy, safety, or delivery profiles that competitors cannot match. If a platform only enables a single drug program, it behaves as an asset company rather than justifying ongoing platform capital allocation.

Episode 245 - Michael Fenn CBO Bexorg thumbnail

Episode 245 - Michael Fenn CBO Bexorg

The BioHub - by Avetix·a month ago

Solving CNS Delivery Demands Multi-Tiered Verification Beyond Merely Crossing Blood-Brain Barriers

CNS therapeutic delivery is a multi-layered hierarchy rather than just crossing the blood-brain barrier. Effective delivery requires achieving adequate exposure in specific anatomical brain regions, verifying target engagement within precise cell types, and achieving proper intracellular trafficking for advanced modalities like ASOs, siRNAs, and AAVs.

Episode 245 - Michael Fenn CBO Bexorg thumbnail

Episode 245 - Michael Fenn CBO Bexorg

The BioHub - by Avetix·a month ago

Seed-Stage Biotech Investors Prioritize Founders Who Form Strong Beliefs Loosely Held

When evaluating early-stage ventures, investors rank the founding team's chemistry, self-awareness, and adaptability as primary criteria. The strongest founders recognize their own knowledge blind spots, aggressively seek complementary talent to address unknowns, and remain flexible enough to modify strong beliefs when presented with new data.

Episode 245 - Michael Fenn CBO Bexorg thumbnail

Episode 245 - Michael Fenn CBO Bexorg

The BioHub - by Avetix·a month ago

Whole Intact Human Brain Perfusion Bypasses Inadequate Animal and Organoid Translational Models

Traditional models like rodents, non-human primates, iPSCs, and brain organoids fail to replicate complex human brain architecture, vasculature, and disease biology. Reperfusing intact donor human brains preserves native blood-brain barriers, endogenous CSF production, and human-specific targets to directly generate human pharmacology preclinically.

Episode 245 - Michael Fenn CBO Bexorg thumbnail

Episode 245 - Michael Fenn CBO Bexorg

The BioHub - by Avetix·a month ago